In the past, two randomized phase III trials with onartuzumab (a monoclonal antibody) and tivantinib (a selective MET TKI inhibitor) in the second/third line were conducted in an unselected NSCLC patient population, and these trials failed to meet their primary endpoint in improving the OS [53,54] (Table S1). Here, MET is linked to non-small cell lung carcinoma.